英国患者用药可及性方案实施经验及对我国的启示  

The implementing experience of patient access schemes in UK and its implication for China

作　　者：常峰[1] 崔鹏磊 夏强[1] 

机构地区：[1]中国药科大学国际医药商学院,江苏南京211198

出　　处：《中国卫生政策研究》2016年第7期60-65,共6页Chinese Journal of Health Policy

基　　金：江苏省普通高校研究生科研创新计划资助项目(SJZZ15_0081)

摘　　要：风险分担协议在提高患者对药品的可及性、降低药品成本效果的不确定性和控制医保基金财务风险等方面取得了显著成效,受到各国政府或保险人的广泛关注。本文系统梳理了英国患者用药可及性方案,包括方案的起源、分类、应用流程、实施效果等。指出我国已基本具备了实施风险分担协议的条件,但仍需进一步明确风险分担协议实施主体,构建风险分担协议标准化流程,同时加强卫生技术评估在卫生资源配置中的应用,以逐步推进风险分担协议的实施等建议,以期完善我国药品谈判制度,提高药品谈判的科学性和效率。The Risk-sharing agreements have achieved remarkable success in improving patients＇ access to drugs,lowering the uncertainty of the drugs cost-effectiveness,financial risk control and other aspects of medical insurance fund,so they have attracted widespread attention by the concerned governments and insurers. This paper systematically reviewed the patient access schemes in UK from several aspects,including the origin of the program,classification,application processes and the implementation effects as well. The results of the research indicated that China has basically met the conditions for implementation of the risk-sharing agreements. In order to gradually promote the risk-sharing agreements implementation,this paper suggests that China should clarify the main root of risk-sharing agreements implementation,establish risk-sharing agreements standardization process and strengthen the application of health technology assessment in health resources allocation to improve the Chinese medicines bargaining system more scientifically and efficiently.

关 键 词：风险分担协议 患者用药可及性方案 卫生技术评估 价格谈判 

分 类 号：R197[医药卫生—卫生事业管理]